Symbols / BYSI Stock $1.71 +2.71% BeyondSpring Inc.

Healthcare • Biotechnology • United States • NCM
BYSI (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Lan Huang Ph.D.
Exch · Country NCM · United States
Market Cap 70.11M
Enterprise Value 66.04M
Income -8.47M
Sales —
FCF (ttm) 15.03M
Book/sh -0.80
Cash/sh 0.30
Employees 44
Insider 10d —
IPO Mar 09, 2017
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.63
PEG —
P/S —
P/B -2.14
P/C —
EV/EBITDA -7.46
EV/Sales —
Quick Ratio 0.93
Current Ratio 1.54
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.21
EPS next Y -0.47
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-12
Earnings (prior) 2022-04-14
ROA -18.56%
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 41.12M
Shs Float 31.69M
Insider Own 14.89%
Instit Own 14.56%
Short Float 6.43%
Short Ratio 121.08
Short Interest 2.19M
52W High 3.44
vs 52W High -50.44%
52W Low 1.21
vs 52W Low 40.91%
Beta 0.51
Impl. Vol. 1.25%
Rel Volume 0.14
Avg Volume 20.12K
Volume 2.88K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $1.66
Price $1.71
Change 2.71%
About

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$1.71
Latest analyst target
3. DCF / Fair value
$6.58
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.71
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-05-02 main Baird — → Outperform $1
2021-12-02 down Jefferies Buy → Hold $5
2021-12-02 down B of A Securities Buy → Underperform $5
2021-12-01 down HC Wainwright & Co. Buy → Neutral —
2021-09-20 main HC Wainwright & Co. — → Buy $65
2021-09-09 init Baird — → Outperform $50
2021-08-04 up HC Wainwright & Co. Neutral → Buy $100
2021-04-05 down HC Wainwright & Co. Buy → Neutral —
2021-01-11 init B of A Securities — → Buy $25
2020-12-29 init Evercore ISI Group — → Outperform $30
2020-06-15 main HC Wainwright & Co. — → Buy $46
2020-03-30 main HC Wainwright & Co. — → Buy $30
2020-02-07 init Jefferies — → Buy $25
2020-01-10 init Nomura — → Buy $34
2019-12-03 init William Blair — → Outperform —
2018-06-22 main Maxim Group Buy → Buy $48
2017-04-04 init Rodman & Renshaw — → Buy $43
News
RSS: Latest BYSI news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-10-17 DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. Beneficial Owner of more than 10% of a Class of Security — 131,311 $1.72 $227,675
2025-10-10 DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. Beneficial Owner of more than 10% of a Class of Security — 13,876 $1.77 $24,720
2025-10-07 DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. Beneficial Owner of more than 10% of a Class of Security — 20,200 $1.76 $35,965
2025-10-02 DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. Beneficial Owner of more than 10% of a Class of Security — 7,665 $1.73 $13,800
2025-09-29 DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. Beneficial Owner of more than 10% of a Class of Security — 1,800 $1.66 $3,045
2025-09-24 DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. Beneficial Owner of more than 10% of a Class of Security — 11,772 $1.68 $20,753
2025-09-19 DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. Beneficial Owner of more than 10% of a Class of Security — 11,267 $1.74 $19,995
2025-09-16 DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. Beneficial Owner of more than 10% of a Class of Security — 4,110 $1.84 $7,603
2025-09-11 DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. Beneficial Owner of more than 10% of a Class of Security — 21,046 $1.90 $40,866
2025-09-08 DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. Beneficial Owner of more than 10% of a Class of Security — 8,999 $1.82 $17,202
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
-100.00%
1.35
Operating Revenue
0.00
0.00
0.00
-100.00%
1.35
Operating Expense
8.95
+2.18%
8.75
-41.95%
15.08
-60.92%
38.59
Research And Development
4.39
+65.96%
2.64
-63.64%
7.27
-71.57%
25.58
Selling General And Administration
4.56
-25.42%
6.11
-21.76%
7.81
-39.97%
13.01
General And Administrative Expense
4.56
-25.42%
6.11
-21.76%
7.81
-39.97%
13.01
Other Gand A
4.56
-25.42%
6.11
-21.76%
7.81
-39.97%
13.01
Total Expenses
8.95
+2.18%
8.75
-41.95%
15.08
-60.92%
38.59
Operating Income
-8.95
-2.18%
-8.75
+41.95%
-15.08
+59.50%
-37.24
Total Operating Income As Reported
-8.95
-2.18%
-8.75
+41.95%
-15.08
+59.50%
-37.24
EBITDA
-8.86
-4.59%
-8.47
+42.70%
-14.78
+58.80%
-35.87
Normalized EBITDA
-9.02
-7.76%
-8.37
+42.85%
-14.65
+58.66%
-35.44
Reconciled Depreciation
0.09
-69.47%
0.28
-5.63%
0.30
+30.17%
0.23
EBIT
-8.95
-2.18%
-8.75
+41.95%
-15.08
+58.22%
-36.10
Total Unusual Items
0.17
+271.88%
-0.10
+25.00%
-0.13
+70.16%
-0.43
Total Unusual Items Excluding Goodwill
0.17
+271.88%
-0.10
+25.00%
-0.13
+70.16%
-0.43
Net Income
-1.01
+90.96%
-11.12
+47.10%
-21.03
+36.82%
-33.28
Pretax Income
-8.62
+1.64%
-8.77
+37.02%
-13.92
+61.45%
-36.12
Net Non Operating Interest Income Expense
0.08
+32.20%
0.06
-81.68%
0.32
+80.90%
0.18
Interest Expense Non Operating
—
—
0.00
-100.00%
0.02
Net Interest Income
0.08
+32.20%
0.06
-81.68%
0.32
+80.90%
0.18
Interest Expense
—
—
0.00
-100.00%
0.02
Interest Income Non Operating
0.08
+32.20%
0.06
-81.68%
0.32
+65.13%
0.20
Interest Income
0.08
+32.20%
0.06
-81.68%
0.32
+65.13%
0.20
Other Income Expense
0.24
+427.03%
-0.07
-108.85%
0.84
-11.44%
0.94
Other Non Operating Income Expenses
0.08
+250.00%
0.02
-97.72%
0.96
-29.79%
1.37
Gain On Sale Of Security
0.17
+271.88%
-0.10
+25.00%
-0.13
+70.16%
-0.43
Tax Provision
0.09
-6.25%
0.10
+4.35%
0.09
-43.56%
0.16
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.03
+271.88%
-0.02
+25.00%
-0.03
+70.16%
-0.09
Net Income Including Noncontrolling Interests
-14.22
+14.83%
-16.69
+23.94%
-21.95
+39.50%
-36.28
Net Income From Continuing Operation Net Minority Interest
4.50
+236.45%
-3.29
+74.83%
-13.09
+60.66%
-33.28
Net Income From Continuing And Discontinued Operation
-1.01
+90.96%
-11.12
+47.10%
-21.03
+36.82%
-33.28
Net Income Continuous Operations
-8.71
+1.69%
-8.87
+36.75%
-14.02
+61.37%
-36.28
Net Income Discontinuous Operations
-5.50
+29.71%
-7.83
+1.32%
-7.93
—
Minority Interests
13.21
+137.18%
5.57
+504.12%
0.92
-69.28%
3.00
Normalized Income
4.37
+235.61%
-3.22
+75.22%
-12.99
+60.56%
-32.94
Net Income Common Stockholders
-1.01
+90.96%
-11.12
+47.10%
-21.03
+36.82%
-33.28
Diluted EPS
-0.02
+92.86%
-0.28
+48.15%
-0.54
+36.47%
-0.85
Basic EPS
-0.02
+92.86%
-0.28
+48.15%
-0.54
+36.47%
-0.85
Basic Average Shares
40.41
+1.69%
39.73
+1.89%
39.00
-0.25%
39.09
Diluted Average Shares
40.41
+1.69%
39.73
+1.89%
39.00
-0.25%
39.09
Diluted NI Availto Com Stockholders
-1.01
+90.96%
-11.12
+47.10%
-21.03
+36.82%
-33.28
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
25.93
-24.43%
34.31
+38.32%
24.81
-46.33%
46.22
Current Assets
20.88
-26.93%
28.58
+55.15%
18.42
-52.19%
38.52
Cash Cash Equivalents And Short Term Investments
12.56
+329.88%
2.92
-45.85%
5.40
-85.52%
37.27
Cash And Cash Equivalents
7.79
+166.46%
2.92
-45.85%
5.40
-84.31%
34.40
Other Short Term Investments
4.78
0.00
-100.00%
0.19
-93.28%
2.87
Prepaid Assets
0.23
-5.42%
0.24
-17.81%
0.29
-40.65%
0.49
Restricted Cash
—
0.00
-100.00%
9.94
0.00
Assets Held For Sale Current
8.02
-68.35%
25.35
+866.70%
2.62
—
Other Current Assets
0.07
+4.41%
0.07
-59.52%
0.17
-77.98%
0.76
Total Non Current Assets
5.05
-11.97%
5.74
-10.19%
6.39
-17.02%
7.70
Net PPE
0.47
-37.37%
0.75
-28.18%
1.05
-85.76%
7.35
Gross PPE
1.11
-14.85%
1.31
-14.58%
1.53
-80.65%
7.90
Accumulated Depreciation
-0.64
-15.70%
-0.55
-14.94%
-0.48
+12.52%
-0.55
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.42
+2.43%
0.41
-0.72%
0.41
-36.11%
0.65
Construction In Progress
—
—
—
0.00
Other Properties
0.42
-32.69%
0.62
-25.98%
0.84
-87.93%
6.98
Leases
0.27
+0.00%
0.27
-0.37%
0.27
+0.00%
0.27
Non Current Accounts Receivable
0.12
+10.62%
0.11
+527.78%
0.02
+125.00%
0.01
Other Non Current Assets
4.46
-8.58%
4.87
-8.47%
5.32
+1470.50%
0.34
Total Liabilities Net Minority Interest
49.92
+2.72%
48.60
+0.69%
48.27
-1.95%
49.23
Current Liabilities
13.58
+23.31%
11.01
+38.35%
7.96
+8.24%
7.35
Payables And Accrued Expenses
1.55
+36.36%
1.14
-61.18%
2.93
-18.34%
3.58
Payables
0.61
+106.42%
0.30
-48.88%
0.58
-47.98%
1.11
Accounts Payable
0.36
+23.05%
0.29
-47.42%
0.56
-48.10%
1.08
Current Accrued Expenses
0.94
+11.67%
0.84
-64.21%
2.35
-4.98%
2.47
Employee Benefits
0.09
+23.29%
0.07
-34.82%
0.11
+31.76%
0.09
Pensionand Other Post Retirement Benefit Plans Current
0.54
-12.09%
0.61
-36.71%
0.97
-27.29%
1.33
Total Tax Payable
0.25
+24700.00%
0.00
-94.44%
0.02
-43.75%
0.03
Income Tax Payable
—
—
—
0.02
Current Debt And Capital Lease Obligation
0.32
+13.48%
0.28
+9.30%
0.26
-73.29%
0.97
Current Debt
—
—
—
—
Other Current Borrowings
—
—
—
—
Current Capital Lease Obligation
0.32
+13.48%
0.28
+9.30%
0.26
-73.29%
0.97
Current Deferred Liabilities
—
—
1.75
+29.61%
1.35
Current Deferred Revenue
—
—
1.75
+29.61%
1.35
Other Current Liabilities
11.17
+24.38%
8.98
+135.88%
3.81
+3020.49%
0.12
Total Non Current Liabilities Net Minority Interest
36.35
-3.31%
37.59
-6.75%
40.31
-3.74%
41.88
Liabilities Heldfor Sale Non Current
3.77
-39.23%
6.20
-21.03%
7.85
—
Long Term Debt And Capital Lease Obligation
0.00
-100.00%
0.31
-47.88%
0.59
-85.26%
4.00
Long Term Capital Lease Obligation
0.00
-100.00%
0.31
-47.88%
0.59
-85.26%
4.00
Tradeand Other Payables Non Current
3.89
+7.69%
3.61
+0.56%
3.59
+0.48%
3.58
Non Current Deferred Liabilities
28.60
+4.38%
27.40
-2.73%
28.17
-17.68%
34.22
Non Current Deferred Revenue
28.60
+4.38%
27.40
-2.73%
28.17
-17.68%
34.22
Other Non Current Liabilities
—
—
—
—
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
-32.16
+2.25%
-32.90
-22.74%
-26.80
-348.32%
-5.98
Common Stock Equity
-32.16
+2.25%
-32.90
-22.74%
-26.80
-348.32%
-5.98
Capital Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Common Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Share Issued
41.12
+2.00%
40.32
+3.30%
39.03
+0.08%
39.00
Ordinary Shares Number
41.12
+2.00%
40.32
+3.30%
39.03
+0.08%
39.00
Additional Paid In Capital
375.66
+0.66%
373.19
+1.24%
368.60
-0.07%
368.86
Retained Earnings
-408.43
-0.25%
-407.43
-2.81%
-396.30
-5.60%
-375.28
Gains Losses Not Affecting Retained Earnings
0.60
-54.94%
1.34
+49.44%
0.89
+105.05%
0.44
Minority Interest
8.17
-56.11%
18.61
+456.67%
3.34
+12.52%
2.97
Other Equity Adjustments
—
—
—
0.44
Total Equity Gross Minority Interest
-23.99
-67.94%
-14.29
+39.11%
-23.46
-680.21%
-3.01
Total Capitalization
-32.16
+2.25%
-32.90
-22.74%
-26.80
-348.32%
-5.98
Working Capital
7.31
-58.41%
17.57
+67.93%
10.46
-66.44%
31.17
Invested Capital
-32.16
+2.25%
-32.90
-22.74%
-26.80
-348.32%
-5.98
Total Debt
0.32
-45.67%
0.59
-30.46%
0.85
-82.93%
4.96
Capital Lease Obligations
0.32
-45.67%
0.59
-30.46%
0.85
-82.93%
4.96
Net Tangible Assets
-32.16
+2.25%
-32.90
-22.74%
-26.80
-348.32%
-5.98
Tangible Book Value
-32.16
+2.25%
-32.90
-22.74%
-26.80
-348.32%
-5.98
Foreign Currency Translation Adjustments
0.60
-54.94%
1.34
+49.44%
0.89
+105.05%
0.44
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-19.77
-20.23%
-16.44
+0.19%
-16.47
+41.48%
-28.15
Cash Flow From Continuing Operating Activities
-19.77
-20.23%
-16.44
+0.19%
-16.47
+41.48%
-28.15
Net Income From Continuing Operations
-14.22
+14.83%
-16.69
+23.94%
-21.95
+39.50%
-36.28
Depreciation Amortization Depletion
0.09
-69.47%
0.28
-5.63%
0.30
+30.17%
0.23
Depreciation
0.09
-69.47%
0.28
-5.63%
0.30
+30.17%
0.23
Depreciation And Amortization
0.09
-69.47%
0.28
-5.63%
0.30
+30.17%
0.23
Other Non Cash Items
0.75
+6.41%
0.70
-35.36%
1.09
+19.08%
0.91
Stock Based Compensation
0.72
-67.98%
2.25
+192.86%
0.77
-53.78%
1.67
Operating Gains Losses
-6.99
—
0.04
+103.45%
-1.07
Gain Loss On Investment Securities
—
—
—
-1.07
Unrealized Gain Loss On Investment Securities
0.00
+100.00%
-0.00
+25.00%
-0.00
+78.95%
-0.02
Gain Loss On Sale Of PPE
—
0.00
-100.00%
0.04
0.00
Change In Working Capital
-0.12
+95.92%
-2.99
-191.04%
3.28
-48.78%
6.41
Change In Receivables
—
—
—
—
Change In Prepaid Assets
0.05
+611.11%
-0.01
-101.16%
0.78
-41.60%
1.33
Change In Payables And Accrued Expense
1.77
+277.67%
-0.99
-327.46%
0.44
+122.26%
-1.96
Change In Accrued Expense
1.84
+575.97%
-0.39
-448.65%
0.11
+108.00%
-1.39
Change In Payable
-0.08
+87.48%
-0.61
-286.20%
0.33
+156.70%
-0.57
Change In Account Payable
-0.08
+87.48%
-0.61
-286.20%
0.33
+156.70%
-0.57
Change In Other Working Capital
-2.00
-99.90%
-1.00
-502.01%
0.25
+118.43%
-1.35
Change In Other Current Assets
0.21
+217.13%
-0.18
-106.85%
2.64
-77.20%
11.58
Change In Other Current Liabilities
-0.14
+81.97%
-0.80
+2.31%
-0.82
+74.23%
-3.19
Investing Cash Flow
10.79
+189.80%
-12.01
-11912.00%
-0.10
-100.55%
18.25
Cash Flow From Continuing Investing Activities
10.79
+189.80%
-12.01
-11912.00%
-0.10
-100.55%
18.25
Net PPE Purchase And Sale
-0.05
+77.68%
-0.22
-124.00%
-0.10
-114.64%
0.68
Purchase Of PPE
-0.05
+77.68%
-0.22
-124.00%
-0.10
-194.12%
-0.03
Sale Of PPE
—
—
0.00
-100.00%
0.72
Capital Expenditure
-0.05
+77.68%
-0.22
-124.00%
-0.10
-194.12%
-0.03
Net Investment Purchase And Sale
3.48
+129.55%
-11.79
0.00
-100.00%
17.56
Purchase Of Investment
-14.95
-16.90%
-12.79
-883.69%
-1.30
+95.96%
-32.20
Sale Of Investment
18.43
+1743.20%
1.00
-23.08%
1.30
-97.39%
49.76
Net Business Purchase And Sale
7.35
0.00
—
—
Gain Loss On Sale Of Business
-6.99
0.00
—
—
Net Other Investing Changes
—
—
—
-0.69
Financing Cash Flow
4.97
-81.45%
26.79
+669525.00%
0.00
-99.88%
3.43
Cash Flow From Continuing Financing Activities
4.97
-81.45%
26.79
+669525.00%
0.00
-99.88%
3.43
Net Issuance Payments Of Debt
0.29
-92.69%
3.91
0.00
+100.00%
-1.57
Issuance Of Debt
0.29
-92.69%
3.91
0.00
0.00
Repayment Of Debt
—
—
0.00
+100.00%
-1.57
Long Term Debt Issuance
0.29
-92.69%
3.91
0.00
0.00
Long Term Debt Payments
—
—
0.00
+100.00%
-1.57
Net Long Term Debt Issuance
0.29
-92.69%
3.91
0.00
+100.00%
-1.57
Net Common Stock Issuance
2.00
-33.33%
3.00
0.00
0.00
Proceeds From Stock Option Exercised
—
0.00
-100.00%
0.00
0.00
Net Other Financing Charges
2.68
-86.50%
19.87
—
5.00
Changes In Cash
-4.01
-140.36%
-1.67
+89.92%
-16.57
-155.99%
-6.47
Effect Of Exchange Rate Changes
0.10
+418.18%
-0.03
+56.58%
-0.08
+89.95%
-0.76
Beginning Cash Position
16.05
-9.59%
17.75
-48.40%
34.40
-17.37%
41.62
End Cash Position
7.79
+166.46%
2.92
-80.95%
15.34
-55.41%
34.40
Free Cash Flow
-19.82
-18.91%
-16.67
-0.56%
-16.57
+41.20%
-28.18
Interest Paid Supplemental Data
0.00
0.00
0.00
-100.00%
0.02
Income Tax Paid Supplemental Data
0.00
-71.43%
0.01
-80.56%
0.04
-90.19%
0.37
Common Stock Issuance
2.00
-33.33%
3.00
0.00
0.00
Issuance Of Capital Stock
2.00
-33.33%
3.00
0.00
0.00
Other Cash Adjustment Outside Changein Cash
-4.35
+66.84%
-13.12
-443.93%
-2.41
—
Sale Of Business
7.35
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category